To elucidate the potential mechanism of Wuji powder in treating polycystic ovary syndrome(PCOS),this study utilized TCMSP database to screen the active ingredients of each constituent drug in Wuji powder.Subsequently,...To elucidate the potential mechanism of Wuji powder in treating polycystic ovary syndrome(PCOS),this study utilized TCMSP database to screen the active ingredients of each constituent drug in Wuji powder.Subsequently,we predicted the target proteins associated with these active ingredients.In parallel,we employed the GeneCards database to identify genes related to PCOS and determined the intersection of drug targets and disease targets using the online tool available at http://bioinformatics.psb.ugent.be/webtools/Venn/.The shared genes were considered as the target proteins of Wuji powder in the treatment of PCOS.Utilizing the String website,we constructed a protein-protein interaction(PPI)network diagram and identified key protein modules and hub genes within the PPI network using Cytoscape 3.7.1 software.Further analysis in the DAVID database involved GO and KEGG pathway enrichment analyses of the genes within the identified key modules.Our investigation revealed a total of 63 active ingredients in Wuji powder with potential therapeutic effects on PCOS,corresponding to 266 drug targets.Intersection with PCOS-related disease targets yielded 174 shared targets.Ten key modules and ten hub genes(TNF,MMP9,AKT1,ECG,VEGFA,PTGS2,IL-6,MAPK3,STAT3,and CXCL8)were identified through network analysis.KEGG pathway enrichment analysis uncovered 58 signaling pathways,including TNF,MAPK,and PI3K-Akt signaling pathways.GO functional annotation delineated five cellular components(CC),nine molecular functions(MF),and 58 biological processes(BP).Noteworthy findings included extracellular space,enzyme binding,and drug response among CC,MF,and BP categories,respectively.These results collectively suggested that Wuji powder might exert its therapeutic effects on PCOS by modulating the TNF/PI3K/AKT signaling pathway.展开更多
Next-generation sequencing(NGS) technology is capable of sequencing millions or billions of DNA molecules simultaneously.Therefore, it represents a promising tool for the analysis of molecular targets for the initial ...Next-generation sequencing(NGS) technology is capable of sequencing millions or billions of DNA molecules simultaneously.Therefore, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(CSCO) and the China Actionable Genome Consortium(CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians,pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure(SOP), data analysis, report, and NGS platform certification and validation.展开更多
Objective： Combined overall survival （OS） analysis of Lux-Lung 3 and Lux-Lung 6 demonstrated that patients with epidermal growth factor receptor （EGFR） exon 19 deletions （Del19） would benefit from first-line se...Objective： Combined overall survival （OS） analysis of Lux-Lung 3 and Lux-Lung 6 demonstrated that patients with epidermal growth factor receptor （EGFR） exon 19 deletions （Del19） would benefit from first-line second generation EGFR tyrosine kinase inhibitors （TKIs） afatinib but not for those with L858R. This study was to investigate the survival difference between first-line first generation EGFR-TKIs and chemotherapy in patients with either Del19 or L858R, and to directly compare OS in these two mutation groups. Methods： Eligibles were all prospective and retrospective studies comparing EGFR-TKIs with conventional chemotherapy or receiving single agent EGFR-TKIs and demonstrating survival analysis based on mutation types. The primary outcome was OS measured as pooled hazard ratios （HRs）. All measures were pooled using random- effects models and 95% confidential interval （95% CI） was calculated. Results： A total of 14 studies incorporating 1,706 patients with either Del19 or L858R were included. Enrolling patients with Del19 or L858R in randomized controlled trials （RCTs）, first-line first generation EGFR-TKIs were associated with no OS benefit, compared with chemotherapy （pooled HR_TKI/Chemo for Del19： 0.82, 95% CI： 0.64- 1.06, P=0.14; pooled HR_TKI/Chemo for L858R： 1.15, 95% CI： 0.85-1.56, P=0.38）. Direct comparison of Del19 with L858R receiving with first-line first generation EGFR-TKIs demonstrated no significant survival difference （pooled HR19/21： 0.88, 95% CI： 0.67-1.16, P=0.37）. Conclusions： Among patients with advanced non-small cell hmg cancer （NSCLC） harboring Del19 and L858R, first-line first generation EGFR-TKIs demonstrated no survival benefit comparing with chemotherapy. Direct comparison between Del19 and L858R revealed no significant survival difference after first-line first generation EGFR-TKIs.展开更多
To systematically assess the clinical efficacy of Salvia miltiorrhiza(SM)in treating pathological scars and provide a reference basis for scar pharmacotherapy,we conducted a comprehensive literature search in both Eng...To systematically assess the clinical efficacy of Salvia miltiorrhiza(SM)in treating pathological scars and provide a reference basis for scar pharmacotherapy,we conducted a comprehensive literature search in both English and Chinese databases from database inception to December 2022.Key search terms included Salvia miltiorhiza,cryptotanshinone,tanshinone IIA,sodium-tanshinol,compound Salvia miltiorrhiza dripping pills,cicatrix,cicatrices,and scar.The inclusion criteria encompassed all clinical randomized controlled studies on the treatment of pathological scars with SM,without regard to blinding or allocation concealment,as well as irrespective of patient nationality,race,or age.Data from the selected literature were subjected to analysis using Rev Man 5.4 software,employing the standard mean difference or weighted mean difference for numerical variables and odds ratios(ORs)for dichotomous variables.Statistical significance was set at P<0.05.Six eligible studies involving a total of 778 patients met the inclusion criteria.The analysis revealed a significant therapeutic efficacy with an OR of 3.83(95%CI:2.65–5.54),indicating a substantially higher therapeutic efficacy rate in SM group compared to the control group.Furthermore,the total effective rate of treatment exhibited an OR of 6.94(95%CI:2.53–19.06),signifying a significantly superior treatment outcome in SM group.Regarding scar scores,no significant improvement was observed in SM group compared to the control group after 3 months of treatment(mean difference[MD]=–0.96,95%CI:–2.29–0.36).However,after 6 months of treatment,the scar score demonstrated a noteworthy improvement in SM group(MD=–1.37,95%CI:–2.44 to–0.30)compared to the control group.In summary,this study affirmed that SM treatment markedly enhanced the therapeutic efficacy and overall treatment efficiency for clinical scar patients,underscoring its positive clinical therapeutic impact on scar patients.展开更多
文摘To elucidate the potential mechanism of Wuji powder in treating polycystic ovary syndrome(PCOS),this study utilized TCMSP database to screen the active ingredients of each constituent drug in Wuji powder.Subsequently,we predicted the target proteins associated with these active ingredients.In parallel,we employed the GeneCards database to identify genes related to PCOS and determined the intersection of drug targets and disease targets using the online tool available at http://bioinformatics.psb.ugent.be/webtools/Venn/.The shared genes were considered as the target proteins of Wuji powder in the treatment of PCOS.Utilizing the String website,we constructed a protein-protein interaction(PPI)network diagram and identified key protein modules and hub genes within the PPI network using Cytoscape 3.7.1 software.Further analysis in the DAVID database involved GO and KEGG pathway enrichment analyses of the genes within the identified key modules.Our investigation revealed a total of 63 active ingredients in Wuji powder with potential therapeutic effects on PCOS,corresponding to 266 drug targets.Intersection with PCOS-related disease targets yielded 174 shared targets.Ten key modules and ten hub genes(TNF,MMP9,AKT1,ECG,VEGFA,PTGS2,IL-6,MAPK3,STAT3,and CXCL8)were identified through network analysis.KEGG pathway enrichment analysis uncovered 58 signaling pathways,including TNF,MAPK,and PI3K-Akt signaling pathways.GO functional annotation delineated five cellular components(CC),nine molecular functions(MF),and 58 biological processes(BP).Noteworthy findings included extracellular space,enzyme binding,and drug response among CC,MF,and BP categories,respectively.These results collectively suggested that Wuji powder might exert its therapeutic effects on PCOS by modulating the TNF/PI3K/AKT signaling pathway.
基金supported by grants from Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (Grant No. 2017B030314120)General Research Project of Guangzhou Science and Technology Bureau (Grant No. 201607010391)+1 种基金National Key Research and Development Program of China (Grant No. 2016YFC1303800)Guangdong Provincial Applied S&T R&D Program (Grant No. 2016B020237006)
文摘Next-generation sequencing(NGS) technology is capable of sequencing millions or billions of DNA molecules simultaneously.Therefore, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(CSCO) and the China Actionable Genome Consortium(CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians,pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure(SOP), data analysis, report, and NGS platform certification and validation.
文摘Objective： Combined overall survival （OS） analysis of Lux-Lung 3 and Lux-Lung 6 demonstrated that patients with epidermal growth factor receptor （EGFR） exon 19 deletions （Del19） would benefit from first-line second generation EGFR tyrosine kinase inhibitors （TKIs） afatinib but not for those with L858R. This study was to investigate the survival difference between first-line first generation EGFR-TKIs and chemotherapy in patients with either Del19 or L858R, and to directly compare OS in these two mutation groups. Methods： Eligibles were all prospective and retrospective studies comparing EGFR-TKIs with conventional chemotherapy or receiving single agent EGFR-TKIs and demonstrating survival analysis based on mutation types. The primary outcome was OS measured as pooled hazard ratios （HRs）. All measures were pooled using random- effects models and 95% confidential interval （95% CI） was calculated. Results： A total of 14 studies incorporating 1,706 patients with either Del19 or L858R were included. Enrolling patients with Del19 or L858R in randomized controlled trials （RCTs）, first-line first generation EGFR-TKIs were associated with no OS benefit, compared with chemotherapy （pooled HR_TKI/Chemo for Del19： 0.82, 95% CI： 0.64- 1.06, P=0.14; pooled HR_TKI/Chemo for L858R： 1.15, 95% CI： 0.85-1.56, P=0.38）. Direct comparison of Del19 with L858R receiving with first-line first generation EGFR-TKIs demonstrated no significant survival difference （pooled HR19/21： 0.88, 95% CI： 0.67-1.16, P=0.37）. Conclusions： Among patients with advanced non-small cell hmg cancer （NSCLC） harboring Del19 and L858R, first-line first generation EGFR-TKIs demonstrated no survival benefit comparing with chemotherapy. Direct comparison between Del19 and L858R revealed no significant survival difference after first-line first generation EGFR-TKIs.
文摘To systematically assess the clinical efficacy of Salvia miltiorrhiza(SM)in treating pathological scars and provide a reference basis for scar pharmacotherapy,we conducted a comprehensive literature search in both English and Chinese databases from database inception to December 2022.Key search terms included Salvia miltiorhiza,cryptotanshinone,tanshinone IIA,sodium-tanshinol,compound Salvia miltiorrhiza dripping pills,cicatrix,cicatrices,and scar.The inclusion criteria encompassed all clinical randomized controlled studies on the treatment of pathological scars with SM,without regard to blinding or allocation concealment,as well as irrespective of patient nationality,race,or age.Data from the selected literature were subjected to analysis using Rev Man 5.4 software,employing the standard mean difference or weighted mean difference for numerical variables and odds ratios(ORs)for dichotomous variables.Statistical significance was set at P<0.05.Six eligible studies involving a total of 778 patients met the inclusion criteria.The analysis revealed a significant therapeutic efficacy with an OR of 3.83(95%CI:2.65–5.54),indicating a substantially higher therapeutic efficacy rate in SM group compared to the control group.Furthermore,the total effective rate of treatment exhibited an OR of 6.94(95%CI:2.53–19.06),signifying a significantly superior treatment outcome in SM group.Regarding scar scores,no significant improvement was observed in SM group compared to the control group after 3 months of treatment(mean difference[MD]=–0.96,95%CI:–2.29–0.36).However,after 6 months of treatment,the scar score demonstrated a noteworthy improvement in SM group(MD=–1.37,95%CI:–2.44 to–0.30)compared to the control group.In summary,this study affirmed that SM treatment markedly enhanced the therapeutic efficacy and overall treatment efficiency for clinical scar patients,underscoring its positive clinical therapeutic impact on scar patients.
